MBX (MBX Biosciences) EBIT per Share : $-3.57 (TTM As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is MBX Biosciences EBIT per Share?

MBX Biosciences's EBIT per Share for the three months ended in Dec. 2024 was $-0.56. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $-3.57.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for MBX Biosciences's EBIT per Share or its related term are showing as below:

MBX's 3-Year EBIT Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 7.9
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

MBX Biosciences's EBIT for the three months ended in Dec. 2024 was $-18.61 Mil.

MBX Biosciences EBIT per Share Historical Data

The historical data trend for MBX Biosciences's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MBX Biosciences EBIT per Share Chart

MBX Biosciences Annual Data

Trend

Dec22

Dec23

Dec24

EBIT per Share

-0.81

-1.11

-6.41

MBX Biosciences Quarterly Data
	Dec22	Sep23	Dec23	Jun24	Sep24	Dec24
EBIT per Share	Get a 7-Day Free Trial			-0.34	-0.31	-	-3.01	-0.56

MBX Biosciences EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

MBX Biosciences's EBIT per Share for the fiscal year that ended in Dec. 2024 is calculated as

	EBIT per Share		(A: Dec. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-68.194	/	10.643
=	-6.41

MBX Biosciences's EBIT per Share for the quarter that ended in Dec. 2024 is calculated as

	EBIT per Share		(Q: Dec. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-18.61	/	33.422
=	-0.56

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.57

MBX Biosciences (NAS:MBX) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

MBX Biosciences EBIT per Share Related Terms

Thank you for viewing the detailed overview of MBX Biosciences's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

MBX Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MBX Biosciences Inc (NAS:MBX) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

11711 N. Meridian Street, Suite 300, Carmel, IN, USA, 46032

Website

https://www.mbxbio.com

MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.